BRCA gene case: James D. Watson, co-founder of double helix structure, rejects patentability of DNA and other amici filings
Background
On Friday, July 20, 2012, the Court of Appeals for the Federal Circuit will re-hear the case Association for Molecular Pathology, et. al. v. United States Patent and Trademark Office, et. al. This case, involving the patent eligibility of DNA–specifically claims directed at two human genes, BRCA1 and BRCA2, associated with an individual’s susceptibility to breast cancer–has been litigated for three years now and has resulted in fractured rulings and widely varying reasoning.